Agencies | Governor
Virginia Regulatory Town Hall
Department of Health Professions
Board of Pharmacy

General Notice
Scheduling of chemicals
Date Posted: 10/21/2016
Expiration Date: 12/1/2016
Submitted to Registrar for publication: YES
30 Day Comment Forum closed. Began on 11/1/2016 and ended 12/1/2016


Pursuant to subsection D of § 54.1-3443, the Board of Pharmacy is giving notice that it will consider placement of chemical substances in Schedule I of the Drug Control Act.  A public hearing will be conducted at 9:00 a.m. on December 12, 2016 at the Perimeter Center, 9960 Mayland Drive, Suite 201, Richmond, VA 23233.  Public comment may also be submitted electronically or in writing prior to December 1, 2016 to Caroline Juran, Executive Director of the Board of Pharmacy to

 As specified in § 54.1-3443, the Virginia Department of Forensic Science (DFS) has identified eight (8) compounds for recommended inclusion by the Board of Pharmacy into Schedule I in the Code of Virginia. A brief description and chemical name for each compound is as follows:

The following compounds are classified as research chemicals. Drugs of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

1. 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names: N,N-Dimethylpentylone, Dipentylone)

2. 4-chloro-alpha-Pyrrolidinovalerophenone (other name: 4-chloro-alpha-PVP)

3. 4-methyl-alpha-Pyrrolidinohexiophenone (other name: MPHP)

4. 4-fluoro-alpha-Pyrrolidinoheptiophenone (other name: 4-fluoro-PV8)

5. 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one (other name: 4-methoxy-PV9)

6. 4-allyloxy-3,5-dimethoxyphenethylamine (other name: Allylescaline)

7. 4-methyl-alpha-ethylaminopentiophenone

 The following compound is a powerful synthetic opioid. DFS recommends placing this compound into Schedule I (§ 54.1-3446(1)).

  1. N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: para-fluoroisobutyryl fentanyl)

 If approved by the Board of Pharmacy, the placement of these substances in Schedule I in the Virginia Drug Control Act shall remain in effect for a period of 18 months from the date of Board action and shall then be de-scheduled unless the Drug Control Act is amended by enactment of legislation by the General Assembly.

Contact Information
Name / Title: Caroline Juran, RPh  / Executive Director
Address: 9960 Mayland Drive
Suite 300
Richmond, 23233
Email Address:
Telephone: (804)367-4578    FAX: (804)527-4472    TDD: ()-